Skip to main content
Premium Trial:

Request an Annual Quote

Cell Biosciences Raises $10M in Private Financing

NEW YORK (GenomeWeb News) – Cell Biosciences has raised $10 million through a Series C private financing, the Palo Alto, Calif.-based firm said today.

The company has developed an "ultrasensitive" nanofluidic immunoassay system designed to analyze proteins in very small biological samples. It said researchers can use the system to discover details about phosphoprotein signaling in a wide variety of biological systems.

Investors in the round included the firm's largest shareholder, the Wellcome Trust. Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, Mitsui Ventures, Royal Bank of Canada, and the Vertical Group also participated in the round.

"This investment should allow us to fully execute our plan to bring this revolutionary proteomics technology to the broad life sciences market," Cell Biosciences CEO Tim Harkness said in a statement.

Cell Biosciences also noted that it will launch its next-generation protein analysis system, the CB1000, at the American Association for Cancer Research annual meeting in Denver later this month.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.